This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 56.6 kDa. The protein migrates as 70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD19 (20-291), Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) was more than 95% and the molecular weight of this protein is around 140-160 kDa verified by SEC-MALS.
Immobilized FMC63 (Mouse IgG2a) at 1 μg/mL (100 μL/well) can bind Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) with a linear range of 1-31 ng/mL (QC tested).
Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) captured on CM5 chip via Anti-Human lgG Fc antibodies surface, can bind FMC63 MAb (Mouse lgG2a) with an affinity constant of 0.17 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) on AHC Biosensor, can bind FMC63 MAb (Mouse lgG2a) with an affinity constant of 0.483 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
293 cells were transfected with FMC63-scFv and RFP tag. 2e5 of the cells were first stained with B. Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251, 3 µg/mL) and C. Human Fc Tag Protein Control, followed by FITC-conjugated Anti-human IgG Fc Antibody. A. Non-transfected 293 cells and C. Human Fc Tag Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251).
Authors: Faude S, Wei J, Muralidharan K, et al.
Journal: Blood advances 2021
Application: Activation study
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.